Transcode Therapeutics (RNAZ) Research & Development (2020 - 2026)

Transcode Therapeutics (RNAZ) has reported Research & Development for 7 consecutive years, with $3.7 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Research & Development rose 43.96% year-over-year to $3.7 million; the trailing twelve-month figure through Jun 2026 stood at $17.4 million (up 80.67% YoY), and the FY2025 full-year result was $13.4 million, up 38.28% from the prior year.
• Research & Development declined to $3.7 million in Q2 2026 per RNAZ's latest filing, from $5.1 million in the prior quarter.
• Across five years, Research & Development topped out at $5.5 million in Q4 2025 and bottomed at $1.2 million in Q3 2024.
• Historically, Research & Development has averaged $3.0 million across 5 years, with a median of $3.0 million in 2022.
• The sharpest annual moves came in 2022 and 2024: Research & Development soared 1137.31% in 2022, then sank 63.28% in 2024.
• Over 5 years, Research & Development stood at $2.7 million in 2022, then increased by 25.19% to $3.4 million in 2023, then climbed by 8.17% to $3.6 million in 2024, then surged by 50.49% to $5.5 million in 2025, then slumped by 32.54% to $3.7 million in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $3.7 million, $5.1 million, and $5.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.